nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—AR—Ergocalciferol—osteoporosis	0.252	0.357	CbGbCtD
Bicalutamide—AR—Estradiol—osteoporosis	0.131	0.185	CbGbCtD
Bicalutamide—CYP2C9—Estropipate—osteoporosis	0.0481	0.0681	CbGbCtD
Bicalutamide—CYP2C19—Cholecalciferol—osteoporosis	0.0298	0.0422	CbGbCtD
Bicalutamide—CYP3A4—Estropipate—osteoporosis	0.028	0.0396	CbGbCtD
Bicalutamide—CYP3A4—Calcitriol—osteoporosis	0.028	0.0396	CbGbCtD
Bicalutamide—CYP2C9—Cholecalciferol—osteoporosis	0.0248	0.0351	CbGbCtD
Bicalutamide—CYP2C19—Estradiol—osteoporosis	0.024	0.034	CbGbCtD
Bicalutamide—CYP2D6—Cholecalciferol—osteoporosis	0.0227	0.0321	CbGbCtD
Bicalutamide—CYP3A4—Ergocalciferol—osteoporosis	0.0224	0.0317	CbGbCtD
Bicalutamide—CYP2C9—Estradiol—osteoporosis	0.02	0.0283	CbGbCtD
Bicalutamide—CYP3A4—Raloxifene—osteoporosis	0.0187	0.0264	CbGbCtD
Bicalutamide—CYP3A4—Ethinyl Estradiol—osteoporosis	0.018	0.0255	CbGbCtD
Bicalutamide—CYP3A4—Cholecalciferol—osteoporosis	0.0144	0.0204	CbGbCtD
Bicalutamide—CYP3A4—Conjugated Estrogens—osteoporosis	0.0132	0.0187	CbGbCtD
Bicalutamide—CYP3A4—Estradiol—osteoporosis	0.0116	0.0164	CbGbCtD
Bicalutamide—AR—Nongenotropic Androgen signaling—SHBG—osteoporosis	0.000485	0.0823	CbGpPWpGaD
Bicalutamide—CYP3A4—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.000359	0.061	CbGpPWpGaD
Bicalutamide—AR—Coregulation of Androgen receptor activity—GSN—osteoporosis	0.000251	0.0427	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—PARK7—osteoporosis	0.000186	0.0316	CbGpPWpGaD
Bicalutamide—Hypertension—Zoledronate—osteoporosis	0.000174	0.000605	CcSEcCtD
Bicalutamide—Hypersensitivity—Alendronate—osteoporosis	0.000174	0.000604	CcSEcCtD
Bicalutamide—Headache—Etidronic acid—osteoporosis	0.000174	0.000603	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000173	0.0006	CcSEcCtD
Bicalutamide—Asthenia—Estropipate—osteoporosis	0.000172	0.000598	CcSEcCtD
Bicalutamide—Visual impairment—Estradiol—osteoporosis	0.000172	0.000597	CcSEcCtD
Bicalutamide—Anorexia—Pamidronate—osteoporosis	0.000172	0.000596	CcSEcCtD
Bicalutamide—Myalgia—Zoledronate—osteoporosis	0.000172	0.000596	CcSEcCtD
Bicalutamide—Chest pain—Zoledronate—osteoporosis	0.000172	0.000596	CcSEcCtD
Bicalutamide—Insomnia—Risedronate—osteoporosis	0.000171	0.000595	CcSEcCtD
Bicalutamide—Anxiety—Zoledronate—osteoporosis	0.000171	0.000594	CcSEcCtD
Bicalutamide—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000171	0.000593	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00017	0.000592	CcSEcCtD
Bicalutamide—Paraesthesia—Risedronate—osteoporosis	0.00017	0.000591	CcSEcCtD
Bicalutamide—Pruritus—Estropipate—osteoporosis	0.00017	0.000589	CcSEcCtD
Bicalutamide—Asthenia—Alendronate—osteoporosis	0.000169	0.000589	CcSEcCtD
Bicalutamide—Hypersensitivity—Ibandronate—osteoporosis	0.000169	0.000588	CcSEcCtD
Bicalutamide—Cough—Conjugated Estrogens—osteoporosis	0.000169	0.000588	CcSEcCtD
Bicalutamide—Dyspnoea—Risedronate—osteoporosis	0.000169	0.000587	CcSEcCtD
Bicalutamide—Dry mouth—Zoledronate—osteoporosis	0.000168	0.000583	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000168	0.000583	CcSEcCtD
Bicalutamide—Fatigue—Ethinyl Estradiol—osteoporosis	0.000168	0.000582	CcSEcCtD
Bicalutamide—Pruritus—Alendronate—osteoporosis	0.000167	0.00058	CcSEcCtD
Bicalutamide—Dyspepsia—Risedronate—osteoporosis	0.000167	0.000579	CcSEcCtD
Bicalutamide—Constipation—Ethinyl Estradiol—osteoporosis	0.000166	0.000577	CcSEcCtD
Bicalutamide—Confusional state—Zoledronate—osteoporosis	0.000166	0.000576	CcSEcCtD
Bicalutamide—Hypersensitivity—Calcitriol—osteoporosis	0.000166	0.000576	CcSEcCtD
Bicalutamide—Cardiac disorder—Estradiol—osteoporosis	0.000166	0.000575	CcSEcCtD
Bicalutamide—Chest pain—Conjugated Estrogens—osteoporosis	0.000165	0.000574	CcSEcCtD
Bicalutamide—Myalgia—Conjugated Estrogens—osteoporosis	0.000165	0.000574	CcSEcCtD
Bicalutamide—Asthenia—Ibandronate—osteoporosis	0.000165	0.000573	CcSEcCtD
Bicalutamide—Anxiety—Conjugated Estrogens—osteoporosis	0.000165	0.000572	CcSEcCtD
Bicalutamide—Nausea—Etidronic acid—osteoporosis	0.000165	0.000572	CcSEcCtD
Bicalutamide—Oedema—Zoledronate—osteoporosis	0.000165	0.000572	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000164	0.00057	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000164	0.00057	CcSEcCtD
Bicalutamide—Diarrhoea—Estropipate—osteoporosis	0.000164	0.00057	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Risedronate—osteoporosis	0.000164	0.000568	CcSEcCtD
Bicalutamide—Infection—Zoledronate—osteoporosis	0.000163	0.000568	CcSEcCtD
Bicalutamide—Fatigue—Risedronate—osteoporosis	0.000163	0.000568	CcSEcCtD
Bicalutamide—Insomnia—Pamidronate—osteoporosis	0.000163	0.000566	CcSEcCtD
Bicalutamide—Pruritus—Ibandronate—osteoporosis	0.000163	0.000565	CcSEcCtD
Bicalutamide—Pain—Risedronate—osteoporosis	0.000162	0.000563	CcSEcCtD
Bicalutamide—Constipation—Risedronate—osteoporosis	0.000162	0.000563	CcSEcCtD
Bicalutamide—Angiopathy—Estradiol—osteoporosis	0.000162	0.000563	CcSEcCtD
Bicalutamide—Shock—Zoledronate—osteoporosis	0.000162	0.000562	CcSEcCtD
Bicalutamide—Paraesthesia—Pamidronate—osteoporosis	0.000162	0.000562	CcSEcCtD
Bicalutamide—Diarrhoea—Alendronate—osteoporosis	0.000162	0.000561	CcSEcCtD
Bicalutamide—Asthenia—Calcitriol—osteoporosis	0.000161	0.000561	CcSEcCtD
Bicalutamide—Nervous system disorder—Zoledronate—osteoporosis	0.000161	0.000561	CcSEcCtD
Bicalutamide—Immune system disorder—Estradiol—osteoporosis	0.000161	0.00056	CcSEcCtD
Bicalutamide—Thrombocytopenia—Zoledronate—osteoporosis	0.000161	0.00056	CcSEcCtD
Bicalutamide—Mediastinal disorder—Estradiol—osteoporosis	0.000161	0.000559	CcSEcCtD
Bicalutamide—Dyspnoea—Pamidronate—osteoporosis	0.000161	0.000558	CcSEcCtD
Bicalutamide—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.00016	0.000556	CcSEcCtD
Bicalutamide—Chills—Estradiol—osteoporosis	0.00016	0.000556	CcSEcCtD
Bicalutamide—Somnolence—Pamidronate—osteoporosis	0.00016	0.000556	CcSEcCtD
Bicalutamide—Skin disorder—Zoledronate—osteoporosis	0.00016	0.000555	CcSEcCtD
Bicalutamide—AR—Notch-mediated HES/HEY network—BGLAP—osteoporosis	0.00016	0.0271	CbGpPWpGaD
Bicalutamide—Pruritus—Calcitriol—osteoporosis	0.000159	0.000553	CcSEcCtD
Bicalutamide—Hyperhidrosis—Zoledronate—osteoporosis	0.000159	0.000553	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000159	0.000552	CcSEcCtD
Bicalutamide—Diarrhoea—Raloxifene—osteoporosis	0.000159	0.000552	CcSEcCtD
Bicalutamide—Dyspepsia—Pamidronate—osteoporosis	0.000159	0.000551	CcSEcCtD
Bicalutamide—Dizziness—Estropipate—osteoporosis	0.000159	0.000551	CcSEcCtD
Bicalutamide—Oedema—Conjugated Estrogens—osteoporosis	0.000158	0.00055	CcSEcCtD
Bicalutamide—Alopecia—Estradiol—osteoporosis	0.000158	0.000548	CcSEcCtD
Bicalutamide—Infection—Conjugated Estrogens—osteoporosis	0.000157	0.000547	CcSEcCtD
Bicalutamide—Diarrhoea—Ibandronate—osteoporosis	0.000157	0.000547	CcSEcCtD
Bicalutamide—Anorexia—Zoledronate—osteoporosis	0.000157	0.000545	CcSEcCtD
Bicalutamide—Decreased appetite—Pamidronate—osteoporosis	0.000157	0.000544	CcSEcCtD
Bicalutamide—Mental disorder—Estradiol—osteoporosis	0.000156	0.000543	CcSEcCtD
Bicalutamide—Dizziness—Alendronate—osteoporosis	0.000156	0.000543	CcSEcCtD
Bicalutamide—Shock—Conjugated Estrogens—osteoporosis	0.000156	0.000541	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000155	0.00054	CcSEcCtD
Bicalutamide—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000155	0.00054	CcSEcCtD
Bicalutamide—Malnutrition—Estradiol—osteoporosis	0.000155	0.00054	CcSEcCtD
Bicalutamide—Fatigue—Pamidronate—osteoporosis	0.000155	0.00054	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Risedronate—osteoporosis	0.000155	0.000538	CcSEcCtD
Bicalutamide—Urticaria—Ethinyl Estradiol—osteoporosis	0.000154	0.000536	CcSEcCtD
Bicalutamide—Pain—Pamidronate—osteoporosis	0.000154	0.000535	CcSEcCtD
Bicalutamide—Constipation—Pamidronate—osteoporosis	0.000154	0.000535	CcSEcCtD
Bicalutamide—Diarrhoea—Calcitriol—osteoporosis	0.000154	0.000535	CcSEcCtD
Bicalutamide—Skin disorder—Conjugated Estrogens—osteoporosis	0.000154	0.000535	CcSEcCtD
Bicalutamide—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000154	0.000534	CcSEcCtD
Bicalutamide—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000154	0.000534	CcSEcCtD
Bicalutamide—Dizziness—Raloxifene—osteoporosis	0.000154	0.000534	CcSEcCtD
Bicalutamide—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000153	0.000532	CcSEcCtD
Bicalutamide—Flatulence—Estradiol—osteoporosis	0.000153	0.000532	CcSEcCtD
Bicalutamide—Tension—Estradiol—osteoporosis	0.000152	0.00053	CcSEcCtD
Bicalutamide—Vomiting—Estropipate—osteoporosis	0.000152	0.00053	CcSEcCtD
Bicalutamide—Dizziness—Ibandronate—osteoporosis	0.000152	0.000528	CcSEcCtD
Bicalutamide—AR—Nuclear Receptors—ESR2—osteoporosis	0.000151	0.0257	CbGpPWpGaD
Bicalutamide—Rash—Estropipate—osteoporosis	0.000151	0.000525	CcSEcCtD
Bicalutamide—Dermatitis—Estropipate—osteoporosis	0.000151	0.000525	CcSEcCtD
Bicalutamide—Anorexia—Conjugated Estrogens—osteoporosis	0.000151	0.000525	CcSEcCtD
Bicalutamide—Nervousness—Estradiol—osteoporosis	0.000151	0.000524	CcSEcCtD
Bicalutamide—Urticaria—Risedronate—osteoporosis	0.000151	0.000523	CcSEcCtD
Bicalutamide—Back pain—Estradiol—osteoporosis	0.00015	0.000522	CcSEcCtD
Bicalutamide—Headache—Estropipate—osteoporosis	0.00015	0.000522	CcSEcCtD
Bicalutamide—Vomiting—Alendronate—osteoporosis	0.00015	0.000522	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.00015	0.000521	CcSEcCtD
Bicalutamide—Abdominal pain—Risedronate—osteoporosis	0.00015	0.00052	CcSEcCtD
Bicalutamide—Body temperature increased—Risedronate—osteoporosis	0.00015	0.00052	CcSEcCtD
Bicalutamide—Muscle spasms—Estradiol—osteoporosis	0.000149	0.000519	CcSEcCtD
Bicalutamide—Rash—Alendronate—osteoporosis	0.000149	0.000517	CcSEcCtD
Bicalutamide—Insomnia—Zoledronate—osteoporosis	0.000149	0.000517	CcSEcCtD
Bicalutamide—Dermatitis—Alendronate—osteoporosis	0.000149	0.000517	CcSEcCtD
Bicalutamide—Feeling abnormal—Pamidronate—osteoporosis	0.000148	0.000516	CcSEcCtD
Bicalutamide—Headache—Alendronate—osteoporosis	0.000148	0.000514	CcSEcCtD
Bicalutamide—Paraesthesia—Zoledronate—osteoporosis	0.000148	0.000513	CcSEcCtD
Bicalutamide—Vomiting—Raloxifene—osteoporosis	0.000148	0.000513	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Pamidronate—osteoporosis	0.000147	0.000512	CcSEcCtD
Bicalutamide—Dyspnoea—Zoledronate—osteoporosis	0.000147	0.00051	CcSEcCtD
Bicalutamide—Rash—Raloxifene—osteoporosis	0.000146	0.000509	CcSEcCtD
Bicalutamide—Dermatitis—Raloxifene—osteoporosis	0.000146	0.000508	CcSEcCtD
Bicalutamide—Somnolence—Zoledronate—osteoporosis	0.000146	0.000508	CcSEcCtD
Bicalutamide—Vomiting—Ibandronate—osteoporosis	0.000146	0.000508	CcSEcCtD
Bicalutamide—Headache—Raloxifene—osteoporosis	0.000145	0.000505	CcSEcCtD
Bicalutamide—Rash—Ibandronate—osteoporosis	0.000145	0.000504	CcSEcCtD
Bicalutamide—Dermatitis—Ibandronate—osteoporosis	0.000145	0.000503	CcSEcCtD
Bicalutamide—Dyspepsia—Zoledronate—osteoporosis	0.000145	0.000503	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000144	0.000501	CcSEcCtD
Bicalutamide—Headache—Ibandronate—osteoporosis	0.000144	0.0005	CcSEcCtD
Bicalutamide—Insomnia—Conjugated Estrogens—osteoporosis	0.000143	0.000498	CcSEcCtD
Bicalutamide—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000143	0.000497	CcSEcCtD
Bicalutamide—Vomiting—Calcitriol—osteoporosis	0.000143	0.000497	CcSEcCtD
Bicalutamide—Decreased appetite—Zoledronate—osteoporosis	0.000143	0.000497	CcSEcCtD
Bicalutamide—Nausea—Estropipate—osteoporosis	0.000142	0.000495	CcSEcCtD
Bicalutamide—Abdominal pain—Pamidronate—osteoporosis	0.000142	0.000495	CcSEcCtD
Bicalutamide—Body temperature increased—Pamidronate—osteoporosis	0.000142	0.000495	CcSEcCtD
Bicalutamide—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000142	0.000494	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000142	0.000493	CcSEcCtD
Bicalutamide—Angioedema—Estradiol—osteoporosis	0.000142	0.000493	CcSEcCtD
Bicalutamide—Rash—Calcitriol—osteoporosis	0.000142	0.000493	CcSEcCtD
Bicalutamide—Fatigue—Zoledronate—osteoporosis	0.000142	0.000493	CcSEcCtD
Bicalutamide—Dermatitis—Calcitriol—osteoporosis	0.000142	0.000493	CcSEcCtD
Bicalutamide—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000141	0.000491	CcSEcCtD
Bicalutamide—Headache—Calcitriol—osteoporosis	0.000141	0.00049	CcSEcCtD
Bicalutamide—Somnolence—Conjugated Estrogens—osteoporosis	0.000141	0.000489	CcSEcCtD
Bicalutamide—Pain—Zoledronate—osteoporosis	0.000141	0.000489	CcSEcCtD
Bicalutamide—Constipation—Zoledronate—osteoporosis	0.000141	0.000489	CcSEcCtD
Bicalutamide—Nausea—Alendronate—osteoporosis	0.00014	0.000487	CcSEcCtD
Bicalutamide—Hypersensitivity—Risedronate—osteoporosis	0.00014	0.000485	CcSEcCtD
Bicalutamide—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000139	0.000484	CcSEcCtD
Bicalutamide—Asthenia—Ethinyl Estradiol—osteoporosis	0.000139	0.000484	CcSEcCtD
Bicalutamide—Syncope—Estradiol—osteoporosis	0.000139	0.000484	CcSEcCtD
Bicalutamide—Nausea—Raloxifene—osteoporosis	0.000138	0.000479	CcSEcCtD
Bicalutamide—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000138	0.000478	CcSEcCtD
Bicalutamide—Pruritus—Ethinyl Estradiol—osteoporosis	0.000137	0.000478	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000137	0.000475	CcSEcCtD
Bicalutamide—Fatigue—Conjugated Estrogens—osteoporosis	0.000137	0.000475	CcSEcCtD
Bicalutamide—Nausea—Ibandronate—osteoporosis	0.000137	0.000474	CcSEcCtD
Bicalutamide—Loss of consciousness—Estradiol—osteoporosis	0.000137	0.000474	CcSEcCtD
Bicalutamide—Asthenia—Risedronate—osteoporosis	0.000136	0.000472	CcSEcCtD
Bicalutamide—Feeling abnormal—Zoledronate—osteoporosis	0.000136	0.000471	CcSEcCtD
Bicalutamide—Cough—Estradiol—osteoporosis	0.000136	0.000471	CcSEcCtD
Bicalutamide—Pain—Conjugated Estrogens—osteoporosis	0.000135	0.000471	CcSEcCtD
Bicalutamide—Constipation—Conjugated Estrogens—osteoporosis	0.000135	0.000471	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Zoledronate—osteoporosis	0.000135	0.000467	CcSEcCtD
Bicalutamide—Hypertension—Estradiol—osteoporosis	0.000134	0.000466	CcSEcCtD
Bicalutamide—Pruritus—Risedronate—osteoporosis	0.000134	0.000466	CcSEcCtD
Bicalutamide—Nausea—Calcitriol—osteoporosis	0.000134	0.000464	CcSEcCtD
Bicalutamide—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000133	0.000462	CcSEcCtD
Bicalutamide—Hypersensitivity—Pamidronate—osteoporosis	0.000133	0.000461	CcSEcCtD
Bicalutamide—Chest pain—Estradiol—osteoporosis	0.000132	0.00046	CcSEcCtD
Bicalutamide—Myalgia—Estradiol—osteoporosis	0.000132	0.00046	CcSEcCtD
Bicalutamide—Anxiety—Estradiol—osteoporosis	0.000132	0.000458	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000131	0.000456	CcSEcCtD
Bicalutamide—Urticaria—Zoledronate—osteoporosis	0.000131	0.000454	CcSEcCtD
Bicalutamide—Abdominal pain—Zoledronate—osteoporosis	0.00013	0.000452	CcSEcCtD
Bicalutamide—Body temperature increased—Zoledronate—osteoporosis	0.00013	0.000452	CcSEcCtD
Bicalutamide—Diarrhoea—Risedronate—osteoporosis	0.00013	0.00045	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.00013	0.00045	CcSEcCtD
Bicalutamide—Dry mouth—Estradiol—osteoporosis	0.000129	0.000449	CcSEcCtD
Bicalutamide—Asthenia—Pamidronate—osteoporosis	0.000129	0.000449	CcSEcCtD
Bicalutamide—Dizziness—Ethinyl Estradiol—osteoporosis	0.000129	0.000446	CcSEcCtD
Bicalutamide—Confusional state—Estradiol—osteoporosis	0.000128	0.000444	CcSEcCtD
Bicalutamide—Pruritus—Pamidronate—osteoporosis	0.000127	0.000443	CcSEcCtD
Bicalutamide—Oedema—Estradiol—osteoporosis	0.000127	0.00044	CcSEcCtD
Bicalutamide—Infection—Estradiol—osteoporosis	0.000126	0.000438	CcSEcCtD
Bicalutamide—Urticaria—Conjugated Estrogens—osteoporosis	0.000126	0.000437	CcSEcCtD
Bicalutamide—Dizziness—Risedronate—osteoporosis	0.000125	0.000435	CcSEcCtD
Bicalutamide—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000125	0.000435	CcSEcCtD
Bicalutamide—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000125	0.000435	CcSEcCtD
Bicalutamide—Shock—Estradiol—osteoporosis	0.000125	0.000433	CcSEcCtD
Bicalutamide—Nervous system disorder—Estradiol—osteoporosis	0.000124	0.000432	CcSEcCtD
Bicalutamide—Vomiting—Ethinyl Estradiol—osteoporosis	0.000124	0.000429	CcSEcCtD
Bicalutamide—Diarrhoea—Pamidronate—osteoporosis	0.000123	0.000428	CcSEcCtD
Bicalutamide—Skin disorder—Estradiol—osteoporosis	0.000123	0.000428	CcSEcCtD
Bicalutamide—Hyperhidrosis—Estradiol—osteoporosis	0.000123	0.000426	CcSEcCtD
Bicalutamide—Rash—Ethinyl Estradiol—osteoporosis	0.000123	0.000426	CcSEcCtD
Bicalutamide—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000122	0.000425	CcSEcCtD
Bicalutamide—Headache—Ethinyl Estradiol—osteoporosis	0.000122	0.000423	CcSEcCtD
Bicalutamide—Hypersensitivity—Zoledronate—osteoporosis	0.000121	0.000421	CcSEcCtD
Bicalutamide—Vomiting—Risedronate—osteoporosis	0.00012	0.000419	CcSEcCtD
Bicalutamide—AR—Nuclear Receptors—VDR—osteoporosis	0.00012	0.0204	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.00012	0.0203	CbGpPWpGaD
Bicalutamide—Rash—Risedronate—osteoporosis	0.000119	0.000415	CcSEcCtD
Bicalutamide—Dermatitis—Risedronate—osteoporosis	0.000119	0.000415	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—COL1A2—osteoporosis	0.000119	0.0202	CbGpPWpGaD
Bicalutamide—Dizziness—Pamidronate—osteoporosis	0.000119	0.000414	CcSEcCtD
Bicalutamide—Headache—Risedronate—osteoporosis	0.000119	0.000412	CcSEcCtD
Bicalutamide—Asthenia—Zoledronate—osteoporosis	0.000118	0.00041	CcSEcCtD
Bicalutamide—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000117	0.000405	CcSEcCtD
Bicalutamide—Pruritus—Zoledronate—osteoporosis	0.000116	0.000404	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000116	0.000401	CcSEcCtD
Bicalutamide—Nausea—Ethinyl Estradiol—osteoporosis	0.000115	0.000401	CcSEcCtD
Bicalutamide—Insomnia—Estradiol—osteoporosis	0.000115	0.000398	CcSEcCtD
Bicalutamide—Vomiting—Pamidronate—osteoporosis	0.000115	0.000398	CcSEcCtD
Bicalutamide—Paraesthesia—Estradiol—osteoporosis	0.000114	0.000396	CcSEcCtD
Bicalutamide—Asthenia—Conjugated Estrogens—osteoporosis	0.000114	0.000395	CcSEcCtD
Bicalutamide—Rash—Pamidronate—osteoporosis	0.000114	0.000395	CcSEcCtD
Bicalutamide—Dermatitis—Pamidronate—osteoporosis	0.000113	0.000394	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—DKK1—osteoporosis	0.000113	0.0193	CbGpPWpGaD
Bicalutamide—Dyspnoea—Estradiol—osteoporosis	0.000113	0.000393	CcSEcCtD
Bicalutamide—Headache—Pamidronate—osteoporosis	0.000113	0.000392	CcSEcCtD
Bicalutamide—Somnolence—Estradiol—osteoporosis	0.000113	0.000392	CcSEcCtD
Bicalutamide—Diarrhoea—Zoledronate—osteoporosis	0.000113	0.000391	CcSEcCtD
Bicalutamide—Nausea—Risedronate—osteoporosis	0.000113	0.000391	CcSEcCtD
Bicalutamide—Pruritus—Conjugated Estrogens—osteoporosis	0.000112	0.000389	CcSEcCtD
Bicalutamide—Dyspepsia—Estradiol—osteoporosis	0.000112	0.000388	CcSEcCtD
Bicalutamide—Decreased appetite—Estradiol—osteoporosis	0.00011	0.000383	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Estradiol—osteoporosis	0.000109	0.00038	CcSEcCtD
Bicalutamide—Fatigue—Estradiol—osteoporosis	0.000109	0.00038	CcSEcCtD
Bicalutamide—Dizziness—Zoledronate—osteoporosis	0.000109	0.000378	CcSEcCtD
Bicalutamide—Constipation—Estradiol—osteoporosis	0.000108	0.000377	CcSEcCtD
Bicalutamide—Pain—Estradiol—osteoporosis	0.000108	0.000377	CcSEcCtD
Bicalutamide—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000108	0.000377	CcSEcCtD
Bicalutamide—Nausea—Pamidronate—osteoporosis	0.000107	0.000372	CcSEcCtD
Bicalutamide—Dizziness—Conjugated Estrogens—osteoporosis	0.000105	0.000364	CcSEcCtD
Bicalutamide—Vomiting—Zoledronate—osteoporosis	0.000105	0.000363	CcSEcCtD
Bicalutamide—Feeling abnormal—Estradiol—osteoporosis	0.000104	0.000363	CcSEcCtD
Bicalutamide—Rash—Zoledronate—osteoporosis	0.000104	0.00036	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Estradiol—osteoporosis	0.000104	0.00036	CcSEcCtD
Bicalutamide—Dermatitis—Zoledronate—osteoporosis	0.000104	0.00036	CcSEcCtD
Bicalutamide—Headache—Zoledronate—osteoporosis	0.000103	0.000358	CcSEcCtD
Bicalutamide—Vomiting—Conjugated Estrogens—osteoporosis	0.000101	0.00035	CcSEcCtD
Bicalutamide—Urticaria—Estradiol—osteoporosis	0.000101	0.00035	CcSEcCtD
Bicalutamide—Abdominal pain—Estradiol—osteoporosis	0.0001	0.000348	CcSEcCtD
Bicalutamide—Body temperature increased—Estradiol—osteoporosis	0.0001	0.000348	CcSEcCtD
Bicalutamide—Rash—Conjugated Estrogens—osteoporosis	9.99e-05	0.000347	CcSEcCtD
Bicalutamide—Dermatitis—Conjugated Estrogens—osteoporosis	9.98e-05	0.000347	CcSEcCtD
Bicalutamide—Headache—Conjugated Estrogens—osteoporosis	9.92e-05	0.000345	CcSEcCtD
Bicalutamide—Nausea—Zoledronate—osteoporosis	9.77e-05	0.00034	CcSEcCtD
Bicalutamide—AR—Nuclear Receptor transcription pathway—VDR—osteoporosis	9.49e-05	0.0161	CbGpPWpGaD
Bicalutamide—Nausea—Conjugated Estrogens—osteoporosis	9.41e-05	0.000327	CcSEcCtD
Bicalutamide—Hypersensitivity—Estradiol—osteoporosis	9.34e-05	0.000325	CcSEcCtD
Bicalutamide—AR—Nuclear Receptors—ESR1—osteoporosis	9.18e-05	0.0156	CbGpPWpGaD
Bicalutamide—Asthenia—Estradiol—osteoporosis	9.1e-05	0.000316	CcSEcCtD
Bicalutamide—Pruritus—Estradiol—osteoporosis	8.97e-05	0.000312	CcSEcCtD
Bicalutamide—Diarrhoea—Estradiol—osteoporosis	8.67e-05	0.000301	CcSEcCtD
Bicalutamide—Dizziness—Estradiol—osteoporosis	8.38e-05	0.000291	CcSEcCtD
Bicalutamide—AR—FOXA1 transcription factor network—ESR1—osteoporosis	8.16e-05	0.0139	CbGpPWpGaD
Bicalutamide—Vomiting—Estradiol—osteoporosis	8.06e-05	0.00028	CcSEcCtD
Bicalutamide—Rash—Estradiol—osteoporosis	7.99e-05	0.000278	CcSEcCtD
Bicalutamide—Dermatitis—Estradiol—osteoporosis	7.99e-05	0.000277	CcSEcCtD
Bicalutamide—Headache—Estradiol—osteoporosis	7.94e-05	0.000276	CcSEcCtD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	7.58e-05	0.0129	CbGpPWpGaD
Bicalutamide—Nausea—Estradiol—osteoporosis	7.53e-05	0.000262	CcSEcCtD
Bicalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	7.48e-05	0.0127	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptor transcription pathway—ESR1—osteoporosis	7.25e-05	0.0123	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—GAPDH—osteoporosis	7.05e-05	0.012	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—RAP1A—osteoporosis	7.05e-05	0.012	CbGpPWpGaD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	6.97e-05	0.0118	CbGpPWpGaD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	6.91e-05	0.0117	CbGpPWpGaD
Bicalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	6.88e-05	0.0117	CbGpPWpGaD
Bicalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	6.82e-05	0.0116	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—VDR—osteoporosis	6.55e-05	0.0111	CbGpPWpGaD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	6.14e-05	0.0104	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	5.84e-05	0.00992	CbGpPWpGaD
Bicalutamide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	5.74e-05	0.00975	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	5.65e-05	0.0096	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	5.6e-05	0.00952	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—ESR1—osteoporosis	5.01e-05	0.00851	CbGpPWpGaD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	5e-05	0.00849	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—ESR2—osteoporosis	4.89e-05	0.0083	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	4.56e-05	0.00774	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CYP19A1—osteoporosis	4.56e-05	0.00774	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	4.5e-05	0.00764	CbGpPWpGaD
Bicalutamide—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	4.29e-05	0.00729	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	4.16e-05	0.00706	CbGpPWpGaD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	3.98e-05	0.00676	CbGpPWpGaD
Bicalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	3.93e-05	0.00667	CbGpPWpGaD
Bicalutamide—CYP2C19—Arachidonic acid metabolism—GPX1—osteoporosis	3.75e-05	0.00637	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	3.69e-05	0.00628	CbGpPWpGaD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	3.66e-05	0.00622	CbGpPWpGaD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	3.63e-05	0.00617	CbGpPWpGaD
Bicalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	3.61e-05	0.00614	CbGpPWpGaD
Bicalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	3.58e-05	0.00608	CbGpPWpGaD
Bicalutamide—CYP2C9—Arachidonic acid metabolism—GPX1—osteoporosis	3.42e-05	0.00581	CbGpPWpGaD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	3.3e-05	0.0056	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP27A1—osteoporosis	3.26e-05	0.00554	CbGpPWpGaD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	3.23e-05	0.00548	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP27A1—osteoporosis	3.22e-05	0.00547	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—ESR1—osteoporosis	3.04e-05	0.00517	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP27A1—osteoporosis	3e-05	0.0051	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP27A1—osteoporosis	2.98e-05	0.00505	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	2.97e-05	0.00504	CbGpPWpGaD
Bicalutamide—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	2.96e-05	0.00503	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP27A1—osteoporosis	2.96e-05	0.00503	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	2.94e-05	0.005	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP27A1—osteoporosis	2.93e-05	0.00499	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—IRS1—osteoporosis	2.84e-05	0.00483	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—osteoporosis	2.63e-05	0.00447	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—osteoporosis	2.61e-05	0.00443	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL6R—osteoporosis	2.6e-05	0.00442	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—U2AF1—osteoporosis	2.59e-05	0.00441	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	2.52e-05	0.00428	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	2.39e-05	0.00407	CbGpPWpGaD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	2.39e-05	0.00406	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	2.36e-05	0.00401	CbGpPWpGaD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	2.2e-05	0.00374	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	2.18e-05	0.00371	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	2.18e-05	0.00371	CbGpPWpGaD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	2.18e-05	0.00371	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	2.07e-05	0.00351	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—ESR2—osteoporosis	2.07e-05	0.00351	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	1.99e-05	0.00338	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL1B—osteoporosis	1.98e-05	0.00336	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	1.96e-05	0.00333	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	1.94e-05	0.0033	CbGpPWpGaD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—osteoporosis	1.94e-05	0.00329	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	1.94e-05	0.00329	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—RPL24—osteoporosis	1.93e-05	0.00328	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	1.89e-05	0.0032	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—POMC—osteoporosis	1.78e-05	0.00303	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—osteoporosis	1.77e-05	0.003	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP19A1—osteoporosis	1.71e-05	0.00291	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP19A1—osteoporosis	1.69e-05	0.00287	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—VDR—osteoporosis	1.64e-05	0.00278	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	1.61e-05	0.00273	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MYC—osteoporosis	1.58e-05	0.00269	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP19A1—osteoporosis	1.58e-05	0.00268	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	1.57e-05	0.00266	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP19A1—osteoporosis	1.56e-05	0.00266	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP19A1—osteoporosis	1.56e-05	0.00264	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP19A1—osteoporosis	1.54e-05	0.00262	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	1.47e-05	0.00249	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	1.44e-05	0.00244	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—TNF—osteoporosis	1.44e-05	0.00244	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	1.43e-05	0.00243	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.31e-05	0.00223	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.31e-05	0.00222	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	1.25e-05	0.00213	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—ESR1—osteoporosis	1.25e-05	0.00213	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.22e-05	0.00208	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	1.17e-05	0.00198	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL6—osteoporosis	1.16e-05	0.00197	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	1.14e-05	0.00194	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PSMA2—osteoporosis	1.11e-05	0.00189	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PSMA5—osteoporosis	1.11e-05	0.00189	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	1.07e-05	0.00181	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	1.03e-05	0.00175	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—POMC—osteoporosis	1.03e-05	0.00175	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	1.02e-05	0.00173	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—ESR2—osteoporosis	9.94e-06	0.00169	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PKM—osteoporosis	9.72e-06	0.00165	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—FDPS—osteoporosis	9.72e-06	0.00165	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	9.72e-06	0.00165	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—POMC—osteoporosis	9.48e-06	0.00161	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—POMC—osteoporosis	9.39e-06	0.0016	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PGLS—osteoporosis	9.21e-06	0.00156	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GPD2—osteoporosis	9.21e-06	0.00156	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PKM—osteoporosis	8.94e-06	0.00152	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—FDPS—osteoporosis	8.94e-06	0.00152	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PKM—osteoporosis	8.86e-06	0.00151	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—FDPS—osteoporosis	8.86e-06	0.00151	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PGLS—osteoporosis	8.47e-06	0.00144	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GPD2—osteoporosis	8.47e-06	0.00144	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ATIC—osteoporosis	8.43e-06	0.00143	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PNP—osteoporosis	8.43e-06	0.00143	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PGLS—osteoporosis	8.4e-06	0.00143	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GPD2—osteoporosis	8.4e-06	0.00143	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—VDR—osteoporosis	7.89e-06	0.00134	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ATIC—osteoporosis	7.75e-06	0.00132	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PNP—osteoporosis	7.75e-06	0.00132	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ATIC—osteoporosis	7.68e-06	0.0013	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PNP—osteoporosis	7.68e-06	0.0013	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CA2—osteoporosis	7.16e-06	0.00122	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—OXCT1—osteoporosis	7.16e-06	0.00122	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—MGLL—osteoporosis	6.98e-06	0.00119	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—OXCT1—osteoporosis	6.59e-06	0.00112	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CA2—osteoporosis	6.59e-06	0.00112	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	6.58e-06	0.00112	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CA2—osteoporosis	6.53e-06	0.00111	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—OXCT1—osteoporosis	6.53e-06	0.00111	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—MYC—osteoporosis	6.52e-06	0.00111	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—MGLL—osteoporosis	6.42e-06	0.00109	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—MGLL—osteoporosis	6.37e-06	0.00108	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—POMC—osteoporosis	6.2e-06	0.00105	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—ESR1—osteoporosis	6.03e-06	0.00102	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	6e-06	0.00102	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—IDH2—osteoporosis	5.94e-06	0.00101	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PKM—osteoporosis	5.84e-06	0.000993	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—FDPS—osteoporosis	5.84e-06	0.000993	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP27A1—osteoporosis	5.58e-06	0.000948	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PGLS—osteoporosis	5.54e-06	0.000941	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GPD2—osteoporosis	5.54e-06	0.000941	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—IDH2—osteoporosis	5.46e-06	0.000927	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ACP5—osteoporosis	5.43e-06	0.000922	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—IDH2—osteoporosis	5.41e-06	0.000919	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	5.36e-06	0.000911	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP27A1—osteoporosis	5.13e-06	0.000872	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP27A1—osteoporosis	5.09e-06	0.000864	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PNP—osteoporosis	5.07e-06	0.000861	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ATIC—osteoporosis	5.07e-06	0.000861	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—TPI1—osteoporosis	5.05e-06	0.000857	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ACP5—osteoporosis	4.99e-06	0.000848	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ACP5—osteoporosis	4.95e-06	0.000841	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	4.89e-06	0.00083	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—P4HB—osteoporosis	4.75e-06	0.000806	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GAPDH—osteoporosis	4.66e-06	0.000791	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—TPI1—osteoporosis	4.64e-06	0.000789	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—TPI1—osteoporosis	4.6e-06	0.000782	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—RAP1A—osteoporosis	4.54e-06	0.000771	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—P4HB—osteoporosis	4.36e-06	0.000741	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—P4HB—osteoporosis	4.33e-06	0.000735	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CA2—osteoporosis	4.31e-06	0.000732	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—OXCT1—osteoporosis	4.31e-06	0.000732	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GAPDH—osteoporosis	4.28e-06	0.000728	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GAPDH—osteoporosis	4.25e-06	0.000721	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—MGLL—osteoporosis	4.2e-06	0.000713	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—RAP1A—osteoporosis	4.17e-06	0.000709	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—RAP1A—osteoporosis	4.14e-06	0.000703	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.96e-06	0.000672	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ENO1—osteoporosis	3.67e-06	0.000623	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PSMA2—osteoporosis	3.61e-06	0.000614	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PSMA5—osteoporosis	3.61e-06	0.000614	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.61e-06	0.000613	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—IDH2—osteoporosis	3.57e-06	0.000606	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ENO1—osteoporosis	3.37e-06	0.000573	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP27A1—osteoporosis	3.36e-06	0.00057	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ENO1—osteoporosis	3.34e-06	0.000568	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PSMA5—osteoporosis	3.32e-06	0.000565	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PSMA2—osteoporosis	3.32e-06	0.000565	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PSMA2—osteoporosis	3.3e-06	0.00056	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PSMA5—osteoporosis	3.3e-06	0.00056	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ACP5—osteoporosis	3.26e-06	0.000555	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—MYC—osteoporosis	3.14e-06	0.000533	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TPI1—osteoporosis	3.04e-06	0.000516	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP19A1—osteoporosis	2.93e-06	0.000498	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—P4HB—osteoporosis	2.85e-06	0.000485	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GAPDH—osteoporosis	2.8e-06	0.000476	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—RAP1A—osteoporosis	2.73e-06	0.000463	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP19A1—osteoporosis	2.7e-06	0.000458	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP19A1—osteoporosis	2.67e-06	0.000454	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ADCY5—osteoporosis	2.4e-06	0.000407	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GPX1—osteoporosis	2.39e-06	0.000406	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ENO1—osteoporosis	2.21e-06	0.000375	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ADCY5—osteoporosis	2.2e-06	0.000374	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—MTHFR—osteoporosis	2.2e-06	0.000374	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GPX1—osteoporosis	2.2e-06	0.000373	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ADCY5—osteoporosis	2.18e-06	0.000371	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GPX1—osteoporosis	2.18e-06	0.00037	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PSMA2—osteoporosis	2.17e-06	0.000369	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PSMA5—osteoporosis	2.17e-06	0.000369	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—MTHFR—osteoporosis	2.03e-06	0.000344	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—MTHFR—osteoporosis	2.01e-06	0.000341	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.76e-06	0.000299	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—POMC—osteoporosis	1.76e-06	0.000299	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—POMC—osteoporosis	1.62e-06	0.000275	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—POMC—osteoporosis	1.61e-06	0.000273	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ADCY5—osteoporosis	1.44e-06	0.000245	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GPX1—osteoporosis	1.44e-06	0.000244	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—MTHFR—osteoporosis	1.32e-06	0.000225	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—POMC—osteoporosis	1.06e-06	0.00018	CbGpPWpGaD
